Andecaliximab
Fibrodysplasia Ossificans Progressiva (FOP) and Non-Hereditary Heterotopic Ossification (NHHO)
Phase 2Active
Key Facts
Indication
Fibrodysplasia Ossificans Progressiva (FOP) and Non-Hereditary Heterotopic Ossification (NHHO)
Phase
Phase 2
Status
Active
Company
About ashibio
āshibio is a private, pre-revenue biotech founded in 2018 and headquartered in Burlingame, California, USA, developing targeted antibody therapies for severe rare bone diseases. The company has two clinical-stage assets: andecaliximab (anti-MMP9) for heterotopic ossification disorders including FOP and non-hereditary HO, and vantictumab (anti-FZD) for autosomal dominant osteopetrosis type 2 (ADO2). With promising preclinical data presented and clinical trials underway or planned, āshibio is positioned in a niche, high-need therapeutic area with limited competition but faces the inherent risks of rare disease drug development.
View full company profile